NEW BRUNSWICK, N.J., May 19, 2021 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8. A total of 16 presentations including 13 abstracts, two educational sessions and one clinical science symposium have been accepted, highlighting data in numerous types of cancer, including leukemia, lymphoma, melanoma and breast, lung and kidney cancer.
"While COVID-19 was justifiably the dominant medical issue and health topic of the past year, the ravages of cancer continued to impact millions of patients and their families in the U.S. and globally," said Howard S. Hochster, MD, FACP, associate director for clinical research at Rutgers Cancer Institute; director of oncology research at RWJBarnabas Health; and distinguished professor of medicine, Rutgers Robert Wood Johnson Medical School. "Inspired and undeterred by the challenges of the pandemic, our team of internationally recognized physicians and translational researchers in the oncology clinical research program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health intensified their efforts and focus on our mission to advance cancer management, care and outcomes in order to help eradicate the disease. We are excited to unveil a dynamic lineup of significant data on a number of key cancers, and new examinations of the impact of racial disparities on cancer risk, survival and care."
Highlights of the accepted abstracts include the following:
- Data from a primary analysis of the fixed-duration (FD) cohort of CAPTIVATE, a multicenter phase 2 study of first-line ibrutinib (I) plus venetoclax (V) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Previously reported results from the minimal residual disease (MRD) cohort found that undetectable MRD was achieved in over two thirds of patients with 12 cycles of I+V, and 30-month progression-free survival rates were ≥95% irrespective of subsequent randomized treatment. Now results from the FD cohort will be presented, evaluating fixed-duration treatment with I+V.
- Data from a phase 2 trial of adjuvant nivolumab in high-risk Stage IIB/IIC melanoma patients. Patients with Stage IIB and IIC melanoma have a 30-45 percent chance of recurrence in the first five years after surgery, yet there are no FDA-approved agents which dramatically improve these patients' chances. This trial seeks to determine if immunotherapy, adjuvant PD-1 inhibition with nivolumab, would improve recurrence-free survival (RFS) at 24 months compared to historical RFS rates.
The full list of presentations at the 2021 ASCO Annual Meeting follows:
Oral Presentations |
||
Abstract No. |
Title |
Presentation Date/Time |
Fixed-duration (FD) first-line treatment |
Monday, June 7, 2021 at 11:30 a.m. EDT |
|
Poster Presentations |
||
Abstract No. |
Title |
Presentation Date/Time |
Polatuzumab vedotin (Pola) + rituximab (R) + |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
HER2 in uterine serous carcinoma: Testing platforms |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Household material hardship and parental distress in |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Body composition measurements and overall survival |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
KEYNOTE-799: Phase 2 trial of pembrolizumab plus |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Clinical activity of fianlimab (REGN3767), a human
|
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Deciphering the molecular landscape and the tumor |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Multiomic analysis to reveal distinct molecular profiles |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Dosing, drug reduction, drug interruption, and drug |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
TCF-001 TRACK (Target Rare Cancer Knowledge): |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Racial disparities in follow-up care of early-stage |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Adjuvant nivolumab in high-risk stage IIb/IIc melanoma |
Friday, June 4, 2021 at 9:00 a.m. EDT |
|
Education Session Presentations |
||
Session title |
Title |
Presentation Date/Time |
Next Steps: |
Integration of Multimodality Treatment in Advanced |
Friday, June 4, 2021 at 9:00 a.m. EDT |
Nutrition, Physical Activity, |
Racial and Ethnic Disparities in the Impact of Obesity |
Friday, June 4, 2021 at 9:00 a.m. EDT |
Clinical Science Symposium |
||
Abstract No. |
Title |
Presentation Date/Time |
Large scale multiomic analysis suggests mechanisms |
Friday, June 4, 2021 at 9:00 a.m. EDT |
About Rutgers Cancer Institute of New Jersey
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
For journalists – contact:
Krista Didzbalis
Media Relations Assistant
908-812-6114
[email protected]
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)
SOURCE Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
![](https://rt.prnewswire.com/rt.gif?NewsItemId=NY84418&Transmission_Id=202105191939PR_NEWS_USPR_____NY84418&DateId=20210519)
Share this article